2025-10-05 - Analysis Report
Okay, here's an analysis of UnitedHealth Group Inc. (UNH) based on the information you provided.

## UNH Stock Analysis - October 5, 2025

**Company Overview:** UnitedHealth Group Inc. is a diversified health care company providing a wide range of products and services.

### 1.  Performance vs. S&P 500 (VOO)

*   **UNH Cumulative Return:** -15.89%
*   **VOO Cumulative Return:** 98.51%
*   **Absolute Divergence:** -115.9 (UNH significantly underperforming VOO)
*   **Relative Divergence:** 8.9 (UNH's underperformance is near the lower end of its historical range relative to VOO).

**Analysis:** UNH has significantly underperformed the S&P 500. The relative divergence suggests that while the underperformance is substantial, it's not unprecedented based on historical data.

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
| ---------- | ------- | ------ | ------- | ----- | ------ |
| 2015-2017  | 58.0%   | 66.4%  | 30.0%   | 0.1   | 199.7  |
| 2016-2018  | 41.0%   | 70.4%  | 26.0%   | 0.1   | 225.6  |
| 2017-2019  | 36.0%   | 73.8%  | 14.0%   | 0.2   | 266.2  |
| 2018-2020  | -43.0%  | 81.2%  | -67.0%  | 0.5   | 317.6  |
| 2019-2021  | 16.0%   | 81.2%  | -30.0%  | 1.5   | 454.8  |
| 2020-2022  | -1.0%   | 81.2%  | 0.0%    | 1.5   | 480.2  |
| 2021-2023  | 24.0%   | 80.8%  | 23.0%   | 0.4   | 476.8  |
| 2022-2024  | -27.0%  | 78.8%  | -47.0%  | 0.3   | 458.1  |
| 2023-2025  | -58.0%  | 78.8%  | -121.0% | 1.3   | 326.2  |

*   **CAGR:** Volatile, ranging from -58% to 58%. Recent periods show negative growth.
*   **MDD:** High Maximum Drawdowns indicate significant risk.
*   **Alpha:**  Generally positive in earlier periods, turning negative more recently, indicating underperformance relative to its risk-adjusted benchmark.
*   **Beta:**  Low Beta values in the earlier periods suggest lower volatility than the market.  Beta increased in the 2019-2022 period, indicating increased correlation with the market.

**Analysis:** The historical Alpha/Beta analysis presents a mixed picture.  Early periods show strong growth and positive alpha, but more recent periods show significant underperformance, high drawdowns, and a fluctuating Beta.  This suggests the company's performance relative to the market has deteriorated.

### 2. Recent Price Action

*   **Last Price:** 360.20
*   **Previous Close:** 353.72
*   **Change:** 1.83%
*   **5-day Moving Average:** 350.73
*   **20-day Moving Average:** 345.39
*   **60-day Moving Average:** 304.36

**Analysis:**  UNH shows recent positive momentum. The price is above all three moving averages, which is bullish. The 1.83% daily increase suggests a potential short-term rally, especially given the context of its previous underperformance.

### 3. Market Risk Indicators and Expected Return

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 60.40 (Approaching overbought territory)
*   **PPO:** -0.26 (Slightly bearish momentum)
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90)"
*   **Recent (20-day) Relative Divergence Change:** -0.3 (Short-term downward trend)
*   **Expected Return:** -139.6% (Significant underperformance vs. S&P 500 over the long term)

**Analysis:**  The MRI suggests high investment suitability based on overall market conditions. However, the RSI nearing overbought levels and the negative PPO indicates that the recent rally might be short-lived. The hybrid signal suggests a buy signal, but the very negative expected return is a significant concern. The recent decrease in relative divergence points to short-term weakness.

### 4. Recent News & Significant Events

*   **Medicare Advantage Reductions and Regulatory Shifts:** Potential negative impact on UNH's investment narrative.
*   **Healthcare Industry Outlook:** Broader context of the healthcare industry.
*   **UNH Lapping the Stock Market (Zacks):** Contradicts the overall negative performance data. Needs further investigation.
*   **Top 3 Dow Stocks (Quantum Computing):** Possibly tangential, unless UNH has a significant stake in quantum computing.
*   **Bernstein Reaffirms Buy Rating:** Positive signal.

**Analysis:** The news is mixed. The Medicare Advantage concerns are a definite risk factor. The "UNH Lapping the Stock Market" headline is an outlier and needs to be verified against other data. Analyst reaffirmation is positive.

### 4-2) Analyst Opinions

*   **Consensus:** Buy (1.96)
*   **Target Price:** Average: 340.50, High: 626.00, Low: 198.00
*   **Recent Rating Changes:** Not specified (but changes might be pending)

**Analysis:** Analyst consensus is generally positive. However, the wide range in target prices indicates uncertainty about UNH's future prospects.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출         |
| ---------- | ----- | ----------- |
| 2025-08-11 | 3.76  | 111.62 B$   |
| 2025-05-07 | 6.9   | 109.58 B$   |
| 2024-11-04 | 6.56  | 100.82 B$   |
| 2024-08-09 | 4.58  | 98.86 B$    |
| 2025-08-11 | 4.58  | 98.86 B$    |

**Analysis:** Revenue is generally trending upwards. EPS is volatile, with a recent dip reported on 2025-08-11. The duplicate entry for 2025-08-11 needs to be clarified.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| ---------- | ---------- | ------------- |
| 2025-06-30 | $111.62B  | 17.93%        |
| 2025-03-31 | $109.58B  | 21.70%        |
| 2024-12-31 | $100.81B  | 21.14%        |
| 2024-09-30 | $100.82B  | 22.84%        |
| 2024-06-30 | $98.86B   | 22.31%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE   |
| ---------- | ---------- | ----- |
| 2025-06-30 | $94.72B   | 3.60% |
| 2025-03-31 | $95.04B   | 6.62% |
| 2024-12-31 | $92.66B   | 5.98% |
| 2024-09-30 | $94.53B   | 6.41% |
| 2024-06-30 | $89.36B   | 4.72% |

**Analysis:** Revenue is increasing, but profit margins and ROE have declined recently.

### 7. Overall Assessment

**Summary:**  UNH shows mixed signals. Recent price action suggests a short-term rally, and analyst consensus is generally positive. However, the company has significantly underperformed the S&P 500, and future expected return is very negative. Profitability metrics have been declining recently. The news headlines point to potential regulatory headwinds.

**Recommendation:**  Given the strong recent underperformance, declining profitability, and regulatory uncertainty, a cautious approach is warranted. While the MRI suggests a buy signal, the negative long-term expected return raises concerns. Further investigation into the factors driving the underperformance is needed before making a strong investment decision.

